Evoke Pharma Inc. (NASDAQ:EVOK) reached a new 52-week high during trading on Thursday . The company traded as high as $7.32 and last traded at $7.30, with a volume of 71,877 shares changing hands. The stock had previously closed at $6.51.

A number of research firms have recently commented on EVOK. Zacks Investment Research upgraded shares of Evoke Pharma from a “hold” rating to a “buy” rating and set a $5.50 price target on the stock in a report on Tuesday, May 3rd. FBR & Co reiterated a “buy” rating on shares of Evoke Pharma in a report on Saturday, May 14th. Brean Capital reiterated a “buy” rating on shares of Evoke Pharma in a report on Thursday, May 12th. Northland Securities began coverage on shares of Evoke Pharma in a report on Wednesday, March 16th. They set an “outperform” rating and a $16.00 price target on the stock. Finally, Rodman & Renshaw reiterated a “buy” rating on shares of Evoke Pharma in a report on Thursday, May 12th. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. Evoke Pharma has an average rating of “Buy” and an average price target of $17.47.

The company’s market cap is $52.92 million. The stock has a 50 day moving average of $5.91 and a 200 day moving average of $4.50.

Evoke Pharma (NASDAQ:EVOK) last announced its quarterly earnings data on Wednesday, May 11th. The specialty pharmaceutical company reported ($0.45) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.41) by $0.04. On average, equities analysts expect that Evoke Pharma Inc. will post ($1.36) EPS for the current fiscal year.

In other news, major shareholder Parters Vii L. P. Domain sold 51,004 shares of the business’s stock in a transaction dated Friday, April 8th. The shares were sold at an average price of $5.28, for a total value of $269,301.12. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, major shareholder Parters Vii L. P. Domain sold 41,478 shares of the business’s stock in a transaction dated Wednesday, April 20th. The shares were sold at an average price of $5.35, for a total transaction of $221,907.30. The disclosure for this sale can be found here.

Evoke Pharma, Inc is a specialty pharmaceutical company. The Company is focused primarily on the development of drugs to treat gastrointestinal (GI) disorders and diseases. The Company is developing EVK-001, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.